Most innovative biotech company announced
Swiss biotech company BioLingus has been selected as the 2016 winner of The CEO Magazine’s Most Innovative Biotech Company award. The innovation award was presented to BioLingus at the London Stock Exchange by senior representatives of European CEO.
With bioengineering techniques inspired by nature, BioLingus has been able to mimic how proteins are preserved over a long time in the seeds of plants, creating a novel delivery system to orally provide peptides and proteins in order to avoid injections. The company’s method can be applied to a multitude of molecules, from peptides to cytokines and other immunotherapies to vaccines.
The award selection panel used a wide range of criteria to decide on the winners of the 2016 awards, lending the critical eye of a collective 205 years of business journalism to the exhaustive information gathered by the award body’s research team. The judges said they were particularly impressed with the technology behind BioLingus’ product and feel that non-invasive delivery of biologicals is the way forward.
“It is an honour for BioLingus’ team to have won this award,” said the biotech company’s co-founder and CEO, Yves Decadt. “It proves the innovative spirit and goals of our company.”
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
